pneumococcal polysaccharide serotype 11A

Pneumococcal polysaccharide serotype 11A is a vaccine candidate consisting of the purified capsular polysaccharide from *Streptococcus pneumoniae* serotype 11A. Developed by Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), this antigen is intended to provide protection against pneumococcal infections caused by this specific serotype, which has emerged as a significant cause of invasive disease in the post-vaccination era. The mechanism of action involves the induction of a serotype-specific immune response, primarily through the production of opsonizing antibodies by B-cells. While serotype 11A is a component of established multivalent vaccines like PPV23 and PCV20, the Erasmus MC program focuses on the specific characterization and potential use of this polysaccharide in optimized or novel vaccine formulations.

Other names

pneumococcal serotype 11A polysaccharideS. pneumoniae serotype 11A capsular polysaccharide